Edgewell Personal Care (EPC) PT Lowered to $88 at RBC Capital Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Barclays Downgrades Edgewell Personal Care (EPC) to Underweight, FY 2018 At Risk
November 10, 2017 6:54 AM ESTBarclays downgraded Edgewell Personal Care (NYSE: EPC) from Equalweight to Underweight with a price target of $55.00 (from $75.00).
Analyst Lauren Lieberman expects competitive pressure to intensify in 2018 and sees knock-on impacts to FY guidance along with potential for continued top-line misses which... More
Pre-Open Movers 11/09: (OTIC) (SAGE) (ROKU) Higher; (VSTO) (OPK) (EPC) Lower (more...)
November 9, 2017 9:23 AM ESTToday's Pre-Open Movers
Otonomy, Inc. (NASDAQ: OTIC) 108.8% HIGHER; announced that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Meniere's disease achieved its primary efficacy endpoint (p value = 0.029). Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Meniere's disease.
Sage Therapeutics (NASDAQ:... More
Edgewell Personal Care Company (EPC) Misses Q4 EPS by 3c, Miss on Revenues; Offers FY18 EPS Guidace Below Consensus
November 9, 2017 6:08 AM ESTEdgewell Personal Care Company (NYSE: EPC) reported Q4 EPS of $1.00, $0.03 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $564.9 million versus the consensus estimate of $588.28 million.
Executive Summary
Net sales on a reported basis were $564.9 million in the fourth quarter of fiscal 2017, a decrease of 7.5% when compared to the prior year quarter, and $2,298.4 million for the full year, a decrease of 2.7% compared to the prior year. Organic net sales were down 8.4% for the quarter and 2.8% for the full year. (Organic net sales exclude sales growth from the Bulldog... More